BACKGROUND AND PURPOSE: The P2Y₁₄ receptor is the newest member of the P2Y receptor family; it is G(i/o) protein-coupled and is activated by UDP and selectively by UDP-glucose and MRS2690 (2-thiouridine-5'-diphosphoglucose) (7-10-fold more potent than UDP-glucose). This study investigated whether P2Y₁₄ receptors were functionally expressed in porcine isolated pancreatic arteries. EXPERIMENTAL APPROACH: Pancreatic arteries were prepared for isometric tension recording and UDP-glucose, UDP and MRS2690 were applied cumulatively after preconstriction with U46619, a TxA₂ mimetic. Levels of phosphorylated myosin light chain 2 (MLC2) were assessed with Western blotting. cAMP concentrations were assessed using a competitive enzyme immunoassay kit. KEY RESULTS: Concentration-dependent contractions with a rank order of potency of MRS2690 (10-fold) > UDP-glucose ≥ UDP were recorded. These contractions were reduced by PPTN {4-[4-(piperidin-4-yl)phenyl]-7-[4-(trifluoromethyl)phenyl]-2-naphthoic acid}, a selective antagonist of P2Y₁₄ receptors, which did not affect responses to UTP. Contraction to UDP-glucose was not affected by MRS2578, a P2Y₆ receptor selective antagonist. Raising cAMP levels and forskolin, in the presence of U46619, enhanced contractions to UDP-glucose. In addition, UDP-glucose and MRS2690 inhibited forskolin-stimulated cAMP levels. Removal of the endothelium and inhibition of endothelium-derived contractile agents (TxA₂, PGF(2α) and endothelin-1) inhibited contractions to UDP glucose. Y-27632, nifedipine and thapsigargin also reduced contractions to the agonists. UDP-glucose and MRS2690 increased MLC2 phosphorylation, which was blocked by PPTN. CONCLUSIONS AND IMPLICATIONS: P2Y₁₄ receptors play a novel vasocontractile role in porcine pancreatic arteries, mediating contraction via cAMP-dependent mechanisms, elevation of intracellular Ca²⁺ levels, activation of RhoA/ROCK signalling and MLC2, along with release of TxA₂, PGF(2α) and endothelin-1.
BACKGROUND AND PURPOSE: The P2Y₁₄ receptor is the newest member of the P2Y receptor family; it is G(i/o) protein-coupled and is activated by UDP and selectively by UDP-glucose and MRS2690 (2-thiouridine-5'-diphosphoglucose) (7-10-fold more potent than UDP-glucose). This study investigated whether P2Y₁₄ receptors were functionally expressed in porcine isolated pancreatic arteries. EXPERIMENTAL APPROACH: Pancreatic arteries were prepared for isometric tension recording and UDP-glucose, UDP and MRS2690 were applied cumulatively after preconstriction with U46619, a TxA₂ mimetic. Levels of phosphorylated myosin light chain 2 (MLC2) were assessed with Western blotting. cAMP concentrations were assessed using a competitive enzyme immunoassay kit. KEY RESULTS: Concentration-dependent contractions with a rank order of potency of MRS2690 (10-fold) > UDP-glucose ≥ UDP were recorded. These contractions were reduced by PPTN {4-[4-(piperidin-4-yl)phenyl]-7-[4-(trifluoromethyl)phenyl]-2-naphthoic acid}, a selective antagonist of P2Y₁₄ receptors, which did not affect responses to UTP. Contraction to UDP-glucose was not affected by MRS2578, a P2Y₆ receptor selective antagonist. Raising cAMP levels and forskolin, in the presence of U46619, enhanced contractions to UDP-glucose. In addition, UDP-glucose and MRS2690 inhibited forskolin-stimulated cAMP levels. Removal of the endothelium and inhibition of endothelium-derived contractile agents (TxA₂, PGF(2α) and endothelin-1) inhibited contractions to UDP glucose. Y-27632, nifedipine and thapsigargin also reduced contractions to the agonists. UDP-glucose and MRS2690 increased MLC2 phosphorylation, which was blocked by PPTN. CONCLUSIONS AND IMPLICATIONS: P2Y₁₄ receptors play a novel vasocontractile role in porcine pancreatic arteries, mediating contraction via cAMP-dependent mechanisms, elevation of intracellular Ca²⁺ levels, activation of RhoA/ROCK signalling and MLC2, along with release of TxA₂, PGF(2α) and endothelin-1.
Authors: Joël Robichaud; Jean-François Fournier; Sébastien Gagné; Jacques Yves Gauthier; Martine Hamel; Yongxin Han; Martin Hénault; Stacia Kargman; Jean-François Levesque; Yaël Mamane; Joseph Mancini; Nicolas Morin; Erin Mulrooney; Jin Wu; W Cameron Black Journal: Bioorg Med Chem Lett Date: 2010-12-28 Impact factor: 2.823
Authors: Juliana I Sesma; Silvia M Kreda; Natacha Steinckwich-Besancon; Hong Dang; Rafael García-Mata; T Kendall Harden; Eduardo R Lazarowski Journal: Am J Physiol Cell Physiol Date: 2012-06-06 Impact factor: 4.249
Authors: Gilles Kauffenstein; Annick Drouin; Nathalie Thorin-Trescases; Hélène Bachelard; Bernard Robaye; Pedro D'Orléans-Juste; François Marceau; Eric Thorin; Jean Sévigny Journal: Cardiovasc Res Date: 2010-01-01 Impact factor: 10.787
Authors: Amanda J Kennedy; Peiran Yang; Cai Read; Rhoda E Kuc; Lucy Yang; Emily J A Taylor; Colin W Taylor; Janet J Maguire; Anthony P Davenport Journal: J Am Heart Assoc Date: 2016-10-14 Impact factor: 5.501
Authors: Zainab S B Abbas; M Liaque Latif; Natalia Dovlatova; Sue C Fox; Stan Heptinstall; William R Dunn; Vera Ralevic Journal: Vascul Pharmacol Date: 2017-12-15 Impact factor: 5.773
Authors: Katherine A Maki; Larisa A Burke; Michael W Calik; Miki Watanabe-Chailland; Dagmar Sweeney; Lindsey E Romick-Rosendale; Stefan J Green; Anne M Fink Journal: Physiol Genomics Date: 2020-06-22 Impact factor: 3.107